@article{10.11648/j.ijn.20220602.19,
  author = {Sebastian Rubino and Katherine Kunigelis and John Lynes and Solmaz Sahebjam and Krupal Patel and Andre Beer-Furlan and James Liu and Michael Vogelbaum and Arnold Etame and John Arrington and Nam Tran},
  title = {Pituitary Metastases Experience in a Neurosurgical Oncology Cohort},
  journal = {International Journal of Neurosurgery},
  volume = {6},
  number = {2},
  pages = {84-89},
  doi = {10.11648/j.ijn.20220602.19},
  url = {https://doi.org/10.11648/j.ijn.20220602.19},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijn.20220602.19},
  abstract = {Previously reported prevalence of pituitary metastases ranges from 0.4-5%. This study’s primary objective is to determine the incidence of pituitary metastases among patients presenting for neurosurgical evaluation with abnormal pituitary imaging findings, and secondarily to report our outcomes. We conducted a single-center, retrospective chart review of patients undergoing neurosurgical evaluation for sellar/suprasellar masses from 2008-2020. Demographic data, presenting symptoms, radiographic features, interventions, and outcomes were analyzed. 78 charts were reviewed; 21 patients (26.9%) had history of prior cancer, and 12 patients (15.4%) were diagnosed with pituitary metastases using pathologic and/or MRI criteria. Of the 21 patients with prior cancer diagnosis, 52.4% were diagnosed with pituitary metastases: 28.6% using MRI criteria and 23.8% using pathologic criteria. Average age of patients with metastases was 61.8 years. Tumor pathology consisted of 33.3% breast, 33.3% lung, 8.3% esophageal, 8.3% renal, 8.3% neuroendocrine and 8.3% melanoma. Pituitary metastasis diagnosis led to one patient’s initial cancer diagnosis. Symptoms at diagnosis included 33.3% headaches, 41.7% endocrinopathies, and 25% visual deficits. Treatment included surgical intervention plus radiation in 41.7%, surgery alone in 8.3%, radiation alone in 25%, and observation alone in 25%. Median follow-up, progression-free-survival, and overall survival was 8.8 months, 4.5 months, and 11.5 months, respectively. Incidence of pituitary metastases in our cohort is higher than previously reported in the general population. Given these findings, there may be a role for early excisional biopsy or resection of sellar/suprasellar lesions in cancer patients, as confirmation of CNS metastatic disease may require targeted brain radiation and/or alteration of systemic therapy.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Pituitary Metastases Experience in a Neurosurgical Oncology Cohort
AU  - Sebastian Rubino
AU  - Katherine Kunigelis
AU  - John Lynes
AU  - Solmaz Sahebjam
AU  - Krupal Patel
AU  - Andre Beer-Furlan
AU  - James Liu
AU  - Michael Vogelbaum
AU  - Arnold Etame
AU  - John Arrington
AU  - Nam Tran
Y1  - 2022/10/21
PY  - 2022
N1  - https://doi.org/10.11648/j.ijn.20220602.19
DO  - 10.11648/j.ijn.20220602.19
T2  - International Journal of Neurosurgery
JF  - International Journal of Neurosurgery
JO  - International Journal of Neurosurgery
SP  - 84
EP  - 89
PB  - Science Publishing Group
SN  - 2640-1959
UR  - https://doi.org/10.11648/j.ijn.20220602.19
AB  - Previously reported prevalence of pituitary metastases ranges from 0.4-5%. This study’s primary objective is to determine the incidence of pituitary metastases among patients presenting for neurosurgical evaluation with abnormal pituitary imaging findings, and secondarily to report our outcomes. We conducted a single-center, retrospective chart review of patients undergoing neurosurgical evaluation for sellar/suprasellar masses from 2008-2020. Demographic data, presenting symptoms, radiographic features, interventions, and outcomes were analyzed. 78 charts were reviewed; 21 patients (26.9%) had history of prior cancer, and 12 patients (15.4%) were diagnosed with pituitary metastases using pathologic and/or MRI criteria. Of the 21 patients with prior cancer diagnosis, 52.4% were diagnosed with pituitary metastases: 28.6% using MRI criteria and 23.8% using pathologic criteria. Average age of patients with metastases was 61.8 years. Tumor pathology consisted of 33.3% breast, 33.3% lung, 8.3% esophageal, 8.3% renal, 8.3% neuroendocrine and 8.3% melanoma. Pituitary metastasis diagnosis led to one patient’s initial cancer diagnosis. Symptoms at diagnosis included 33.3% headaches, 41.7% endocrinopathies, and 25% visual deficits. Treatment included surgical intervention plus radiation in 41.7%, surgery alone in 8.3%, radiation alone in 25%, and observation alone in 25%. Median follow-up, progression-free-survival, and overall survival was 8.8 months, 4.5 months, and 11.5 months, respectively. Incidence of pituitary metastases in our cohort is higher than previously reported in the general population. Given these findings, there may be a role for early excisional biopsy or resection of sellar/suprasellar lesions in cancer patients, as confirmation of CNS metastatic disease may require targeted brain radiation and/or alteration of systemic therapy.
VL  - 6
IS  - 2
ER  - 

Copy | Download